cyrilzakka/clinical-trials huggingface dataset:
A Study to Evaluate Satisfaction of the Personal Health Record Platform for Chronic Patients in Emergency Department

The investigators developed the service showing patient health record altogether which is managed by each hospital separately and recording the patient health information based on mobile application. This study is a multi-centered study involving two hospitals, providing services to patients, care givers and medical staffs. After the participants use this service, the investigators evaluate the effectiveness and satisfaction of this service through questionnaires and in-depth interviews.

\<Background\> Emergency situations for chronic patients are increasing due to aging, eating habits and lifestyle changes. For chronic patients, comprehensive health records and utilization are important for health care and emergency situations. In particular, in the event of an emergency, information on the patient's personal health records, such as recent surgery records, disease history, prescription and dosage history is needed immediately, but it is difficult to check separately for each hospital. In addition, in emergencies, it may take more time for proper treatment to take place if patients themselves cannot directly talk about their medication or past surgical history, or if they are unable to communicate with patients. Recently, conditions have been prepared for the collection and utilization of personal health record information due to changes in policy and technology environment, making it possible to provide services for emergency patients with chronic diseases.

\<Objective\> To establish a service for collection and utilization of medical records (care, examination, surgery, prescription records) and PGHD for chronic patients and to evaluate its effectiveness.

\<Design\> Mixed methods study (questionnaires and interview)

\<Setting\> At the Samsung Medical Center and the Dong-A Medical Center.

\<Enrollment\> 400 patients(care givers)

\<Intervention\>

1. 400 patients(care givers) are enrolled and use the personal health wallet service. (Personal Health Record service)
2. The participants fill out questionnaire to evaluate the service
3. Some of them are invited for an in-depth interview.

Eligibility Criteria:
\<Inclusion Criteria\>

* A chronic patient (or his or her care giver) who visits the emergency department and has a plan to visit outpatient or other hospitals in one month of the visiting emergency department.
* Adults over 19 years old.
* Those who voluntarily agreed to participate in the research

\<Exclusion Criteria\>

* Anyone who disagrees with this study
* Patients who are not conscious when leaving the emergency room, patients who are not aware of or are not aware of their orientation, patients who are not aware of their level of awareness, or people who are in shock or in deep shutdown situations) (Even in the above cases, caregivers can be included in the clinical trial target if they are present. )
Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin

This is a randomized double-blinded study examining the effect of topical Acetyl Hexapeptide-8 AH8) for improving the cosmetic appearance and experience of oily skin.

The purpose of this randomized double-blinded study is to investigate whether topical Acetyl Hexapeptide-8 can improve oily skin. Up to 15 adult subjects will be recruited. Each half of the face will randomized to receive either topical treatment with AH8 10% Lotion formulated in Cetaphil® Moisturizing Facial Lotion or the placebo vehicle treatment consisting of Cetaphil® Moisturizing Facial Lotion only, at twice daily application for 4 weeks.

The study consists of a total of 3 sessions: baseline visit, and at 2 weeks and 4 weeks for follow up assessment. Subjects will also be asked to complete an Oily Skin Self-Assessment Scale (OSSAS) and an Oily Skin Impact Scale (OSIS) survey at the first session. They will be filling out two OSSAS surveys (one for each side of the face) at the second and third sessions. The OSSAS survey includes subjective assessment of four components of oily skin: visual, blotting, tactile, and sensation. At each visit, the cosmetic appearance the facial skin will be scored clinically by a dermatologist using a validated 3-point scale for shine (1 = high, 2, moderate or 3 = low), and oiliness (1 = normal, 2 = easily visible or 3 = extensive) 16. High-resolution digital photographs of the facial skin with the use of photography and facial analysis instrumentation will be taken at baseline and at each visit to document facial appearance and for image analysis of shine level. Sebum of the left and right cheeks will be measured by a sebumeter to correlate to the oily appearance noted on the high resolution facial photographs.

Eligibility Criteria:
Inclusion Criteria:

* Subjects over the age of 18

Exclusion Criteria:

* Recent intradermal botulinum neurotoxin injection within the last 6 months.
* Known hypersensitivity to AH8
* Ablative resurfacing procedures to the face within 6 months of the study initiation
* Report of pregnancy or breastfeeding
* Use of immunosuppressive drugs
Evaluation of Pigmented Skin Lesions With MelaFind(R) System

The purpose of this clinical trial is to demonstrate that MelaFind®, a new instrument that uses machine vision for non-invasive early detection of cutaneous pigmented malignant melanoma, is safe and effective. MelaFind® acquires digital images of the lesion with illumination in different spectral bands, from visible to near infrared, and automatically analyzes these images. Diagnostic accuracy of MelaFind® and that of study dermatologists will be evaluated. The reference standard will be final interpretation of lesions by central dermatohistopathology.


Eligibility Criteria:
Inclusion Criteria:

* The lesion is pigmented (i.e., melanin, keratin, blood)
* Clinical management of the lesion by the examining dermatologist is either biopsy of the lesion in toto, or 3-month follow-up of the lesion
* The diameter of the pigmented area is between 2 and 22 millimeters
* The lesion is accessible to the MelaFind hand-held imaging device
* The patient, or a legally authorized representative, has consented to participate in the study and has signed the Informed Consent Form

Exclusion Criteria:

* The patient has a known allergy to isopropyl alcohol
* The lesion has been previously biopsied, excised, or traumatized
* The skin is not intact (e.g., open sores, ulcers, bleeding)
* The lesion is within 1 cm of the eye
* The lesion is on mucosal surfaces (e.g., lips, genitals)
* The lesion is on palmar hands
* The lesion is on plantar feet
* The lesion is on or under nails
* The lesion is located on or in an area of visible scarring
* The lesion contains foreign matter (e.g., tattoo, splinter, marker)
Early Rehabilitation After Total Hip Replacement

The purpose of this study is to determine whether supervised progressive resistance training is effective in the early phase after Total Hip Replacement. The investigators hypothesise that 10 weeks of supervised, progressive resistance training immediately after discharge will lead to increased functional performance, muscle strength and muscle power compared to standard rehabilitation consisting of home-based exercise.

After total hip replacement (THR) surgery there is a documented deficit in muscle strength and functional performance. There is a lack of evidence concerning the effectiveness of postoperative physiotherapy and training, however a few small studies have shown promising effect of resistance training.

The present study will provide new and important knowledge concerning the effect of different rehabilitation strategies after THR. This might lead to a change in the rehabilitation regimes and faster and better recovery after THR surgery.

Eligibility Criteria:
Inclusion Criteria:

* Total hip replacement for osteoarthrosis
* Living within 30 km from the hospital
* Motivated to attend training 2 times/week in 10 weeks
* Reduced functional ability measured as: HOOS score \< 67
* written informed consent

Exclusion Criteria:

* Comorbidities such as cancer, neuromuscular diseases, heart diseases etc.
* Cognitive impairment
* Body mass index \> 35
* Resurfacing prosthesis
* Scheduled additional prosthetic surgery in lower extremity within 6 months
A Register Based Prospective Study During Implementation of a New Cup

In a prospective register-based study, we aim to evaluate the implant survival, clinical outcomes and X-ray findings by following a cohort of patients operated with the Trident II cup.

Data will be collected from a cohort consisting of minimum 500 total hip arthroplasties. The patients will be recruited from multiple high volume centers in Sweden. To determine if there is evidence of inferiority as per benchmarking recommendations by The Orthopaedic Data Evaluation Panel the following parameters will be studied: Clinical parameters such as EQ-5D, Oxford Hip Score and Forgotten Joint Score, preoperative and after 1, 3, 6 and 10 years. Conventional radiography will be done preoperatively, postoperatively, 3, 6 and 10 years after total hip replacement. CTMA will be done postoperatively, 3 and 6 month and 2 years after total hip replacement.

Eligibility Criteria:
Inclusion Criteria:

* Primary hip replacement
* Eligible for uncemented fixation of the acetabular component
* Suitable for one of the stem designs from Stryker Orthopaedics
* Accepts follow-up according to the study protocol

Exclusion Criteria:

* Difficulties to understand written information due to language problems or other reasons
* Use of augments needed
* Acute hip fracture
* Tumor in the hip joint
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stimulate the immune system in different ways and stop tumor cells from growing.

PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib in treating patients with stage IIIB or stage IV non-small cell lung cancer.

OBJECTIVES:

Primary

* Determine the optimal biologic dose (OBD) of celecoxib that is necessary to decrease peripheral blood lymphocyte CD4+ and CD25+ T-lymphocyte regulatory cells in patients with stage IIIB or IV non-small cell lung cancer.

Secondary

* Determine the OBD of this drug that is necessary to decrease peripheral blood lymphocyte FOXP3 levels in these patients.

OUTLINE: This is a nonrandomized, dose-escalation study.

Patients receive oral celecoxib twice daily on days 1-7 in the absence of unacceptable toxicity.

Cohorts of 3 patients receive escalating doses of celecoxib until the optimal biologic dose (OBD) is determined. The OBD is defined as the lowest dose that results in the maximum decrease in peripheral blood lymphocyte CD4+ and CD25+ T-lymphocyte regulatory cells and FOXP3 levels where no dose-limiting toxicity occurs. An additional 15 patients are treated at the OBD.

PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed non-small cell lung cancer
* Stage IIIB or IV disease
* Radiographically measurable disease
* 18 and over
* Performance status: ECOG 0-2
* Renal: Creatinine ≤ 2 mg/dL
* Negative pregnancy test
* Fertile patients must use effective contraception
* More than 4 weeks since prior chemotherapy
* Endocrine therapy: More than 4 weeks since prior corticosteroids; No concurrent corticosteroids, including chronic corticosteroids, except for medically-indicated topical steroids
* Radiotherapy: More than 4 weeks since prior radiotherapy
* More than 4 weeks since other prior anticancer therapy
* More than 4 weeks since prior non-cytotoxic investigational agents
* At least 72 hours since prior nonsteroidal anti-inflammatory drugs (NSAIDs)

Exclusion Criteria:

* pregnant or nursing
* comorbid disease, psychiatric condition, chronic medical condition, or laboratory abnormality that would preclude study treatment or compliance with study requirements
* hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study reagent
* history of gastrointestinal ulceration, bleeding, or perforation
* other concurrent cyclooxygenase-2 or -3 inhibitors
* other concurrent NSAIDs
The Influence of Tissue Adhesive to Palatal Donor Site Healing.

CTG was harvested from 21 patients in each group. Donor site was treated with either GS (control) or GS+CY (test). Palatal tissue thickness, graft dimensions, working time (WT) and primary bleeding time were recorded intraoperatively. The data of pain perception (PP) will be measured using visual analog scale, quantity of analgesics (QA), secondary bleeding (SB), epithelization level (EL), and color match (CM) will be assessed prospectively. these outcomes will be evaluated in the first 7 days and 14th, 21th, and 28th days. Patient reported outcomes will be recorded using OHIB 14 questionnaire.


Eligibility Criteria:
Inclusion Criteria:

* age ≥18;
* PPS indication that needs CTG in anterior mandible;
* stable periodontium after phase I therapy;
* full-mouth plaque and bleeding scores \<15%

Exclusion Criteria:

* previous palatal harvesting history;
* unstable endodontic conditions;
* tooth mobility at surgical site;
* systemic disease;
* pregnancy;
* use of medications with potential adverse effects to periodontal tissues
Dexmedetomidine for Postoperative Analgesia After Bariatric Surgery

The purpose of this study is to determine if Dexmedetomidine given at the end of surgery will reduce postoperative morphine consumption and improve postoperative quality of recovery as compared to morphine in patients undergoing laparoscopic bariatric surgery.

effect of Dexmedetomidine bolus on postoperative morphine requirements

Eligibility Criteria:
Inclusion Criteria:

* Body Mass Index \> 40 kg/m2 or BMI \> 35 kg/m2 with comorbid conditions such as hypertension, diabetes or sleep apnea
* American Society of Anesthesiologists class I or II
* Undergoing laparoscopic sleeve gastrectomy bariatric surgery

Exclusion Criteria:

* Allergy to morphine or its derivatives
* Allergy to α-2 adrenergic agonists
* weight over 180 kg
* history of uncontrolled hypertension
* heart block greater than first degree
* prolonged QT interval
* clinically significant neurologic, cardiovascular, renal, hepatic, or gastrointestinal diseases
* received an opioid analgesic medication within a 24 h period prior to surgery
* history of alcohol, drug abuse or chronic opioid intake
* history of psychiatric disorder
* pregnant or breastfeeding.
A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.


Eligibility Criteria:
Inclusion Criteria:

* Male or Female, African American (self-reported), ≥12 years of age
* Moderate to severe asthma requiring treatment with an inhaled corticosteroid
* Diagnosis of asthma for at least 6 months

Exclusion Criteria:

* Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)
* Any significant disease or disorder that may jeopardize a subject's safety
Alcohol And Sexual Risk Behavior

The current study proposes to develop, refine, and conduct a preliminary randomized controlled trial (RCT) of an innovative prevention program that is the first to (a) simultaneously target heavy episodic drinking (HED), sexually aggressive behavior (SAB), and risky sexual behavior (RSB) among college men; (b) integrate personalized feedback and cognitive training strategies; and (c) target the five major modifiable risk factors for SAB: HED, impersonal sex, misperceptions of sexual interest, rape-supportive attitudes, and peer influence. The program will be computer-delivered as this approach is well received by college students.

The study will include three phases (pilot feasibility n=10; pilot acceptability/efficacy n=40; RCT n=140), with 190 men at risk for HED, RSB, and SAB. Participants in the RCT will be randomly assigned to either the computer-based program or services as usual at 2 large public universities in the midwest and southwest U.S. The three study phases will address the following aims:

AIM ONE: Examine the feasibility of the computer administered personalized feedback and cognitive training approach (Phase I; n=10), and the acceptability and efficacy of individual intervention components based on skills assessments and interviews at 1-month follow-up (Phase II; n=40). Data from Phases I and II will be used to modify and streamline the intervention prior to the RCT (Phase III).

AIM TWO: In an RCT (n=140), evaluate whether the prevention program impacts cognitive training and personalized feedback targets at 1-month follow-up, relative to services as usual (SAU). Cognitive training targets include (a) enhanced focus on women's affect; (b) reduced focus on women's non-affective cues; and (c) correction of over-perceptions of women's sexual interest. Personalized feedback targets include (a) increased readiness to change; (b) increased perceptions of risk; and (c) reduced misperceptions of peer attitudes and behaviors.

AIM THREE: Evaluate whether the prevention program shows short-term effects on attitudinal (e.g., rape supportive and sociosexual attitudes) and behavioral outcomes (SAB, HED, and RSB) at 1-month follow-up.

Eligibility Criteria:
Inclusion Criteria:

* 1) be male college students aged 18-19 at ASU or Iowa;
* 2) report at least one binge-drinking episode in the last month;
* 3) be unmarried and not engaged to be married;
* 4) be heterosexual or bisexual;
* 5) be dating or sexually active with women; and
* 6) be above the mean in rape supportive attitudes relative to 3000 college males in prior studies conducted at the two sites.

Exclusion Criteria:

* Do not meet the inclusion criteria
HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults

This phase IV trial examines the impact of an education program on the human papilloma virus (HPV) and its effects on the acceptance and completion rates of a free HPV vaccination program in underserved adult patients. Participating in the HPV educational program may increase the HPV vaccination rates among low income uninsured adult patients and ultimately prevent HPV related cancers.

PRIMARY OBJECTIVES:

I. Determine the acceptability and completion rates of free HPV vaccination among the underserved adult patients at the Volunteer in Medicine Clinic (VIM) in Jacksonville, Florida.

II. Determine if an education program on HPV vaccination increases the acceptability of free HPV vaccination among the underserved adult patients at the Volunteer in Medicine Clinic (VIM) in Jacksonville, Florida.

III. Determine the baseline prevalence of HPV vaccination completion rates among VIM patients age 18-45.

IV. Determine if there are differences in acceptance and completion rates of HPV vaccination, among VIM patients of different sex, age (18-26 versus \[vs\] 27-45), ethnicity or race, following an education program on HPV as part of this protocol participation.

VI. Assessing possible barriers for vaccine series completion. VII. Determine if follow up intervention increases completion rate of free HPV vaccine series within 9 months.

OUTLINE:

Patients receive educational materials on HPV and are asked of their willingness to proceed with the first HPV vaccination. Patients who express interest in receiving the HPV vaccination, then receive the first dose of the HPV vaccine and the next 2 doses approximately 2 months and 6 months following the initial vaccine.

Eligibility Criteria:
Inclusion Criteria:

* Male and female adults patients seen at Volunteers in Medicine ages 18-45 years of age who read and understand English or Spanish

Exclusion Criteria:

* Children (under 18 years of age)
* Individuals who had previously received any dose of HPV vaccine
Ultrasound-Assisted Lumbar Puncture in Children

The aim of this study is to determine if emergency physician performed ultrasound-assisted lumbar puncture improves first-time success rates in a pediatric population. This will be done by comparison with current landmark-based approach to the procedure.


Eligibility Criteria:
Inclusion Criteria:

* Patient less than 19 years of age
* Requiring a lumbar puncture as part of their work-up, as determined by the treating pediatric emergency physician.

Exclusion Criteria:

* • Patients with known spine or spinal cord abnormalities

  * Patients with ventricular shunts
  * Patients deemed too unstable to have procedure performed
  * Patients at risk for significant bleeding (coagulopathy, thrombocytopenia, etc)
  * Parents unable to give consent or patients unable to assent for an acute reason
The Effects of Thoracic Spine Mobilizations in Individuals With Neck Pain.

To determine the affects of Physical Therapists clinical reasoning using thoracic spine mobilization for neck pain compared to a standard protocol.

The purpose of this research is to compare the effects of two commonly used, safe, thoracic spine treatments: grade 1-4 as performed by Cleland et. al. and grade 1-4 mobilization to the thoracic spine as selected by the Physical Therapist for cervical spine pain. The immediate effects of thoracic spine mobilization have been shown to facilitate greater range of motion increases in the cervical spine and greater pain decreases within a treatment session and on follow-up visits. There is no research utilizing pain threshold perception as an objective outcome of these treatments. Only one study compared the two treatment techniques and concluded that future research should be completed which includes manual therapy for the thoracic spine. (Cleland 2007) If the PT identifies an appropriate patient they will ask if they are interested in being a research subject. The Physical Theapist recruiting subjects all have completed their Doctor of Physical Therapy Degree and have advanced training in manual Physical Therapy. The techniques employed are considered standard practice and are defined as entry level skills by the Comission of Accredicdation of Physical Therapy Programs. These techniques are typically taught in DPT degree programs.

Eligibility Criteria:
Inclusion Criteria:

* Patients with Neck Pain
* Ages 18 - 60

Exclusion Criteria:

* Red flags: leg weakness, night pain, history of cancer, upper motor neuron signs, infection, tumors, osteoporosis, fracture (Boissonnault, 2011) (Cleland, 2004), cervical stenosis, CNS involvement, signs consistent with nerve root compression, previous surgery, pending legal action

The inclusion and exclusion above represent a conservative approach based on combining criteria of recent studies in published review articles. (Cross, 2011; Walser, 2009